Hexima Limited developing HXP124, a new prescription treatment for onychomycosis, announced an updated timeline to delivery of results from its phase IIb clinical trial which is being conducted in patients with onychomycosis. The pace of enrolment of patients into the trial, which is being conducted in Australia and New Zealand, has been modestly impacted by State travel restrictions, business closures and mandated lock downs due to the Coronavirus pandemic. These events have not affected in any way the integrity of the trial but are likely to result in data from the clinical trial being available one calendar quarter later than previously anticipated. Hexima has recently added additional clinical investigator sites and adopted other measures to accelerate patient recruitment and enrolment. Accordingly, Hexima expects to announce results of its phase IIb clinical trial of HXP124 in patients with onychomycosis in the second quarter of 2022.